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ABSTRACT
The development of cancer is driven by the accumulation of many oncogenesisrelated genetic alterations and tumorigenesis is triggered by complex networks of
involved genes rather than independent actions. To explore the epistasis existing
among oncogenesis-related genes in lung cancer development, we conducted pairwise
genetic interaction analyses among 35,031 SNPs from 2027 oncogenesis-related
genes. The genotypes from three independent genome-wide association studies
including a total of 24,037 lung cancer patients and 20,401 healthy controls with
Caucasian ancestry were analyzed in the study. Using a two-stage study design
including discovery and replication studies, and stringent Bonferroni correction for
multiple statistical analysis, we identified significant genetic interactions between
SNPs in RGL1:RAD51B (OR=0.44, p value=3.27x10-11 in overall lung cancer and
OR=0.41, p value=9.71x10-11 in non-small cell lung cancer), SYNE1:RNF43 (OR=0.73, p
value=1.01x10-12 in adenocarcinoma) and FHIT:TSPAN8 (OR=1.82, p value=7.62x10-11
in squamous cell carcinoma) in our analysis. None of these genes have been identified
from previous main effect association studies in lung cancer. Further eQTL gene
expression analysis in lung tissues provided information supporting the functional
role of the identified epistasis in lung tumorigenesis. Gene set enrichment analysis
revealed potential pathways and gene networks underlying molecular mechanisms
in overall lung cancer as well as histology subtypes development. Our results provide
evidence that genetic interactions between oncogenesis-related genes play an
important role in lung tumorigenesis and epistasis analysis, combined with functional
annotation, provides a valuable tool for uncovering functional novel susceptibility
genes that contribute to lung cancer development by interacting with other modifier
genes.

INTRODUCTION

be detected solely by studying the main effect of either
gene alone. There is growing evidence showing that
epistasis is involved in lung cancer development [9,1314]. In 2014, researchers conducted a genome-wide genegene interaction analysis and identified an epistasis effect
between rs2562796 (gene: HIBCH) and rs16832404 (gene:
c2orf88) in lung cancer development [9]. Neither of these
two genes has been identified from main effect association
analysis before, suggesting that genetic interactions,
especially those among novel variants, remain unrevealed
in lung cancer study. To date, the reports on large-scale
genetic interaction analysis in human diseases remain
quite limited because of the challenge in high-dimensional
data analysis.
The development of cancer is driven by the
accumulation of many oncogenesis-related genetic
alterations and tumorigenesis is triggered by complex
networks of involved genes rather than independent
actions [15-18]. Extensive molecular studies have revealed

Lung cancer, as one of the most common cancers
worldwide, has a complex disease mechanism and
both genetic and environmental factors, as well as the
interactions among those factors contribute to development
of this deadly disease [1-9]. The past decade has witnessed
the harvest of genome-wide association studies (GWAS)
in complex disease studies and several common variants
predisposing to lung cancer have been identified including
TERT at 5p15, TP63 at 3q28, HLA region at 6p21, and
CHRNB4-CHRNA3-CHRNA5 region at 15q25, etc [2-6].
However, the discovered genetic variants only account for
a limited fraction of the heritability of lung cancer [10].
Genetic interactions, i.e., epistasis is believed to contribute
to a considerable proportion of the missing heritability
in complex human diseases [11-12]. Epistasis, is the
phenomenon where the effect of one gene is dependent
on the effects of one or more other genes that may not
www.oncotarget.com
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RESULTS

interactions existing between selected cancer driver genes,
such as cooperation of MYC and RAS in transformation
and immortalization process, and BRCA1 and P53 in
breast cancer development, etc [19-20]. These are only
tips of iceberg and much more latent genetic interactions
among cancer-related genes are waiting to be identified.
We hypothesized that there are considerable interactions
among oncogenesis-related genes underlying lung
tumorigenesis and a GxG interaction association analysis
provides us a potent tool to explore it. An epistasis study
among oncogenesis-related genes in lung cancer will help
us identify oncogenes or tumor suppressors affecting
early stages of lung cancer development that cannot be
captured by single-locus analysis; provide insights about
the connected pathways and genetic networks involved in
lung cancer development; and discover novel targets for
disease treatment. And the results from interaction analysis
can be leveraged to improve lung cancer risk assessment.
Lung cancer is a heterogeneous disease and
researchers have identified vast differences in genomic
attributes, such as specific variants, gene mutation, gene
expression and DNA methylation profile, etc., between
adenocarcinoma (ADE) and squamous cell carcinoma
(SQC) lung cancer subtype [4, 21-22]. However, the
knowledge about epistatic features in lung cancer subtypes
is limited. Performing a stratified epistasis analysis by
lung cancer histology subtype will provide insights
concerning tumor-subtype specific genetic interactions
and gene networks. The availability of large lung cancer
GWAS data from international collaboration enables
us to conduct a large-scale epistasis analysis among
oncogenesis-related genes in overall lung cancer as well
as lung cancer subtypes. In this study, we collected the
genotype data from 44,438 individuals with Caucasian
ancestry, including 20,401 controls and 24,037 cases,
from three independent cohorts. It is currently the largest
genetic interaction analysis in lung cancer study to our
knowledge.

The genotypes from three independent lung cancer
GWAS including a total of 24,037 lung cancer patients
and 20,401 health controls with European ancestry
were collected for the study. Demographic and clinical
characteristics as well as sample sizes are summarized
in Table 1. A comprehensive list of 2,027 cancer-related
genes, including DNA binding proteins, transcription
factors, transcriptional regulators, and other genes
regulating protein expression, were identified and used
to filter the search space for genetic interactions between
carcinogenesis-related genes (Figure 1A). The study
strategy is presented in Figure 1B. A stringent Bonferroni
corrected significance cutoff was calculated based on the
number of pair-wise tests between independent SNPs and
p value < 1.95x10-10 was used for significance threshold in
final meta-analysis.

Discovery study
By use of the “fast-epistasis” option in PLINK to
quickly screen for interactions, an exhaustive pairwise
interaction analysis among cancer-related genes was
conducted in the overall lung cancer cohort (ALL) as
well as the stratified group by NSCLC, ADE and SQC
histology subtype using lung cancer OncoArray GWAS
data in the discovery stage. The sample size in the cohorts
included 14,260 controls plus 18,401 overall lung cancer
cases, 13,593 NSCLC cases, 7,157 ADE cases and 4,612
SQC cases, respectively. In the ALL interaction analysis,
there were 102, 734, 7113 and 70145 SNP pairs when
we used p value < 1x10-7, 1x10-6, 1x10-5 and 1x10-4 as
the significance threshold, respectively. We decided to
use 1x10-6 as the significance cutoff value to provide a
balance between including excess false positive results
versus missing potential signals. There were 717, 917

Figure 1: Carcinogenesis-related gene selection and statistical analysis strategy used in the study. A. Categorization of the
molecular functions of the selected 2027 cancer-related genes (DAVID). B. Flow chart of statistical analysis strategy in the study.
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Table 1: Summary and characteristics of three independent GWAS datasets used in the study
OncoArray
Affymetrix
GELCC
N = 32,661
N = 10,347
N = 1,430
Discovery

Replication 1

Replication 2

No. Sample

Cases
n = 18,401

Controls
n = 14,260

Cases
n = 4,950

Controls
n = 5,397

Cases
n = 686

Controls
n = 744

Agea

63.8

61.6

62.9

60.4

61.6

64.9

Male (%)

62.5

60.3

53.9

53.4

38.9

35.6

Never (%)

9.7

32.1

9.7

29.8

13.0

40.1

Former (%)

38.7

39.7

36.2

35.2

87.0c

59.9c

Current (%)

51.6

28.2

54.1

34.9

NA

NA

Packyr

40.7

29.8

28.9

27.6

NA

NA

Smoking status

b

Histology
NSCLC (%)

73.9

63.3

70.8

ADE (%)

38.9

36.4

40.7

SQC (%)

25.1

19.9

14.3

a and b, average statistics for age and packyr (pack year) are provided. c, includes both current and former smokers.
and 1118 SNP pairs with Z-score p value < 1x10-6 from
NSCLC, ADE and SQC interaction analysis, respectively
(Appendix 3 Supplementary Table 1). The selected SNP

pairs were submitted to more stringent logistic regression
interaction analysis. A total of 678, 673, 883 and 1062
SNP pairs had logistic interaction p value < 1x10-5 from

Figure 2: Imputed genetic interaction analysis in candidate regions. 1-4 plots display the results at all lung cancer, NSCLC,

ADE and SQC cohort, respectively. A. Interaction map with SNPs from ~ 30 kb flanking regions using imputed genotype at discovery
dataset. The X and Y axis denote the SNPs at each of the gene. The color shade indicates the change of -log10(p) of interaction p value. The
signals were highlighted in grey-colored boxes. B. Signals from analysis using imputed genotype. The X and Y axis denote location (bp)
of each of the SNP in one gene and Z axis displayed the -log10(p) from the interaction analysis, the plane in dash line indicated p value of
1.95x10-10. Black, blue and green color denotes the results from OncoArray, Affymetrix and GELCC imputed genotype data analysis and
red color denotes the results from joint analysis combining all the datasets.
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Table 2: Signals from interaction analysis in genotyped discovery data, replication data sets and joint analysis
OncoArray_
genotyped

Affymetrix_
imputed

GELCC_
imputed

Joint

OR

P

OR

P

OR

OR

9.63E-03 0.22 2.68E02
6.71E-04 0.24 4.35E02
3.56E-04 0.20 2.00E02
4.66E-04 0.34 8.62E02
4.84E-04 0.29 5.66E02
9.61E-03 2.08 1.85E02
9.84E-03 2.08 1.81E02
7.36E-03 2.08 1.81E02
9.38E-02 1.26 6.03E02

0.46 3.24E09
0.43 1.59E10
0.43 3.11E10
0.42 6.60E11
0.44 3.27E11
1.39 1.01E09
1.39 1.01E09
1.39 8.30E10
1.14 8.30E07

0.32

0.41 3.81E10
0.40 9.71E11
1.16 9.50E09
1.17 5.46E09
1.17 4.79E09

0.18

SNP1

A1
(MAF)

GENE1

SNP2

A1
(MAF)

rs74826777

A (0.01)

RGL1

rs4902626

A (0.21) RAD51B

0.49

2.83E-07

0.30

rs74826777

A (0.01)

RGL1

rs2877496

A (0.21) RAD51B

0.47

5.20E-08

0.18

rs74826777

A (0.01)

RGL1

rs1474960

G (0.22) RAD51B

0.48

1.39E-07

0.16

rs74826777

A (0.01)

RGL1

rs17835218 A (0.22) RAD51B

0.46

1.14E-08

0.17

rs74826777

A (0.01)

RGL1

rs17835244 C (0.22) RAD51B

0.48

2.89E-08

0.17

rs3764240

A (0.03)

CD109

rs851984

A (0.39) ESR1

1.36

1.63E-06

1.41

rs3764240

A (0.03)

CD109

rs851983

G (0.39) ESR1

1.37

9.29E-07

1.41

rs3764240

A (0.03)

CD109

rs851982

G (0.39) ESR1

1.37

9.86E-07

1.43

rs7783961

A (0.28)

CALCR

rs2505532

A (0.41) RET

1.14

4.08E-07

1.10

rs74826777

A (0.01)

RGL1

rs2877496

A (0.21) RAD51B

0.45

1.56E-07

0.16

rs74826777

A (0.01)

RGL1

rs1474960

G (0.22) RAD51B

0.44

7.23E-08

0.13

rs9677398

A (0.28)

THADA rs2648875

A (0.24) PVT1

1.17

4.41E-07

1.11

rs7570751

G (0.28)

THADA rs2648875

A (0.24) PVT1

1.17

3.07E-07

1.11

rs6544655

G (0.28)

THADA rs2648875

A (0.24) PVT1

1.17

6.05E-07

1.11

1.68E-03 0.24 6.20E02
6.84E-04 0.22 3.92E02
8.62E-02 1.34 7.20E02
8.44E-02 1.47 1.87E02
7.29E-02 1.39 4.36E02

rs6544657

G (0.28)

THADA rs2648875

A (0.24) PVT1

1.17

2.93E-07

1.11

8.42E-02 1.38 4.56E02

1.17 7.91E09

0.38

rs1554783

G (0.25)

SYNE1

rs10515157 A (0.16) RNF43

0.84

1.78E-06

0.81

3.55E-03 0.69 3.70E02

0.82 1.29E08

0.57

rs2131556

A (0.21)

PTPRU

rs4646

A (0.27) CYP19A1 0.82

8.54E-07

0.87

G (0.25)

SYNE1

rs10515157 A (0.16) RNF43

0.79

3.04E-07

0.79

rs2758791

G (0.26)

SYNE1

rs10515157 A (0.16) RNF43

0.79

2.31E-07

0.79

0.82 2.70E08
0.78 3.18E09
0.78 4.28E09

0.37

rs1554783

8.79E-02 0.64 2.48E02
8.69E-03 0.52 5.47E03
8.68E-03 0.58 1.48E02

rs6716971

G (0.06)

BRE

rs6787614

A (0.12) RUVBL1

1.63

1.12E-06

2.12

2.07E-04 5.30 8.92E02

1.74 6.03E10

0.26

rs1882898

A (0.38)

FHIT

rs1705235

C (0.05) TSPAN8

1.51

1.45E-07

2.26

2.91E-02 9.95 9.31E04

1.57 5.95E09

0.01

rs11135724

G (0.27)

LOXL2

rs208311

G (0.30) P2RX7

0.81

6.63E-07

0.82

3.76E-02 0.58 6.03E02

0.81 6.31E09

0.52

GENE2

P

P

Q

0.14
0.06
0.15
0.11
0.41
0.41
0.41
0.62

NSCLC

0.11
0.46
0.24
0.41

ADE

0.22
0.38

SQC

There are 37, 50, 33 and 67 SNP pairs with meta-analysis p value < 0.05 in replication study and only SNP pairs with
interaction p value < 0.1 in both the two replication datasets are reported in Table 2. OR, p values from each individual dataset
as well as the joint meta-analysis are reported, and numbers highlighted in red color indicate the overall meta-analysis p values
< 1.95x10-10 (Bonferroni corrected significance cutoff).
in Affymetrix GWAS and GELCC GWAS datasets
separately and then conducted meta-analysis to combine
the information from both studies. 37, 50, 33 and 67 SNP
pairs had a replication meta-analysis p value < 0.05 with
consistent interaction effects (either risk or protective
effect) across all three different datasets in ALL, NSCLC,
ADE and SQC, respectively (Appendix 1). A final meta-

ALL, NSCLC, ADE and SQC cohort, respectively. These
SNP pairs were further submitted to replication study.

Replication study
In the replication study, we first performed logistic
gene-gene interaction studies for the selected SNP pairs
www.oncotarget.com
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analysis was conducted to combine the information from
both discovery and replication studies at these replicated
SNP pairs and overall ORs and p values were reported.
Table 2 displays the results for SNP pairs with logistic
interaction p value < 1x10-5 in discovery dataset and <
0.1 from each of the two replication datasets. In ALL
lung cancer cohort, we identified a significant interaction
effect between rs74826777, located in gene RGL1, and
five SNPs located at gene RAD51B. The interaction
OR varied from 0.46 to 0.49 with p values ranging
from 1.14x10-8 to 2.83x10-7in discovery study. In the
replication study, the interaction OR varied from 0.16 to
0.30 with p values ranging from 3.56x10-4 to 9.63x10-3in
Affymetrix replication data; and OR varied from 0.20 to
0.34 with p value ranging from 2.00x10-2 to 8.62x10-2 in
GELCC replication data. In the overall meta-analysis,
three SNP pairs had p value < 1.95x10-10 (highlighted
in red in Table 2). The most significant SNP pair was
rs74826777:rs17835244 with an overall interaction OR
of 0.44 and p value of 3.27x10-11. One of the SNP pairs,
rs74826777:rs1474960, also displayed significant signals
in NSCLC cohort with OR 0.40 and p value 9.71x10-11 in
final meta-analysis.
In addition to the significant interaction effect
detected between RGL1 and RAD51B, we also identified
some interactions with consistent evidence across
discovery and replication studies but not achieving
significance threshold (p value < 1.95x10-10) in the overall
meta-analysis, such as CD109:ESR1 gene pair in ALL
cohort, THADA:PVT1 in NSCLC cohort, SYNE1:RNF43
from ADE cohort, and BRE:RUVBL1 and FHIT:TSPAN8
from SQC cohort (Table 2). Suggestive evidence for
genetic interactions between SYNPO2 and BRCA1 gene
were found in ADE cohort. 8 SNP pairs had significant
interaction effect in the OncoArray discovery dataset
and GELCC replication study. However, no supporting
evidence was identified in Affymetrix replication data
(Appendix 1). The most significant signal came from
rs6828669:rs16941 with overall OR of 0.85 and p value
of 3.95x10-9.

were found with interaction p value < 1x10-6 in ALL and
NSCLC discovery cohort, respectively (Appendix 2).
We further validated the signals in replication datasets
and performed joint analysis to combine all information.
Figure 2B displayed the significant signals from the
imputed genotype analysis. In each plot, X and Y axis
denoted the location of SNPs at each of the gene and Z
axis displayed the -log10(p) in the joint meta-analysis, the
plane in dash line indicated Bonferroni corrected p value
threshold (1.95x10-10). For the genetic interaction between
RGL1 and RAD51B gene, we identified 7 and 3 SNP pairs
with joint p value < 1.95x10-10 from the ALL lung cancer
and NSCLC cohort, respectively. The most significant
SNP pair in ALL cohort is rs74826777:rs8006890
with an OR of 0.39 and p value of 1.68x10-11; and
rs74826777:rs17835244 with OR 0.38 and p value of
3.76x10-11 in NSCLC cohort (Figure 2B 1&2, Appendix
2). The interaction analysis using imputed genotype data
reinforced the finding for interaction between RGL1 and
RAD51B gene.
In the ADE and SQC cohort, we identified some
evidence for genetic interactions in SYNE1:RNF43 and
FHIT:TSPAN8 gene pairs in discovery and replication
study but none of the SNP pairs achieved the significance
level (Table 2). Fortunately, the intensive interaction
mapping using imputed genotype provided us strong
evidence for epistasis between these two gene pairs. In
ADE subtype, we identified 111 SNP pairs with metaanalysis p value < 1.95x10-10 coming from 14 SNPs at
SYNE1 and 8 SNPs at RNF43 gene. The most significant
interaction came from SNP pair rs12213593:rs11079348
with OR 0.73 and p value of 1.01x10-12. In SQC cohort, 21
SNP pairs, coming from 16 SNPs at FHIT and 3 SNPs at
TSPAN8, had meta-analysis p value < 1.95x10-10. The most
significant SNP pair was rs1882898:rs1798081 with OR
0.60 and p value of 7.62x10-11 (Figure 2B 3&4, Appendix
2).

Imputation analysis in candidate regions

In order to investigate how the genetic variation
at one locus impacted the risk effect at the other locus
in the identified significant SNP pairs we further
conducted stratified association analysis. Take the
rs74826777:rs17835244 pair from RGL1:RAD51B
gene pair as an example, these two SNPs had p value
of 0.16 and 0.02 in single-locus association analysis
in ALL lung cancer cohort, respectively, indicating no
significant main effect in lung cancer development. In
the stratified analysis, for individuals with no minor allele
at rs74826777 (RGL1 gene), rs17835244 (RAD51B)
does not impact lung cancer risk (p value = 0.51); but
for individuals with at least one copy of minor alleles
at rs74826777, rs17835244 displays a protective effect
for lung cancer with OR 0.46 and p value of 1.22x10-8

Epistasis in lung cancer risk development

For each unique gene pair reported in Table 2, we
further imputed the ~30kb flanking regions harboring the
involved SNPs using the genotypes from the OncoArray
GWAS data to increase the density of markers in the
candidate regions. Figure 2A displayed the interaction
mapping using imputed genotype in discovery data. In
each plot, X and Y-axis denote the imputed SNPs in each
of the gene and -log10(p) was represented by shades of
red color in the heatmap. More potential significant SNPs
pairs were revealed in the intensive interaction mapping
and highlighted in grey-colored boxes. For example, 16
and 25 SNP pairs, between RGL1 and RAD51B gene,
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(Figure 3A). This association of rs17835244 with lung
cancer is so significant that it achieves a genome-wide
significance level in a standard GWAS study (p < 5x108
). Similar results were detected in RAD51B:RGL1 gene
pair in NSCLC cohort (Figure 3A). These results present
a perfect example explaining epistasis contributes to lung
cancer risk development which cannot be revealed by
single-locus main effect screening.
For the RNF43:SYNE1 gene pair identified in ADE
cohort, rs10515157 slightly increases the ADE risk (OR =
1.11 and p value = 6.85x10-3) among individuals carrying
no minor allele at rs1554783; whereas decreases ADE
risk among individuals carrying at least one minor allele
at rs1554783 (OR = 0.85 and p value = 1.90x10-4). For
the FHIT:TSPAN8 gene pair identified in SQC cohort,
rs1882898, located in FHIT, slightly decreases SQC risk
among individuals with no minor allele at rs1705235 (OR
= 0.94 and p value = 2.50x10-2); whereas increases SQC
risk among individuals with at least one minor allele at
rs1705235 (OR = 1.41 and p value = 1.48x10-5). These
results displayed reverse risk effect at one genetic locus
when the genotype was different at second locus.
We further analyzed the lung cancer risk effect with

joint genotypes at the SNP pairs, with no minor allele
at either locus (0/0) as reference group. For SNP pair
rs74826777:rs1474960, from RGL1:RAD51B gene pair,
individuals with genotype 1/0 had a lung cancer risk effect
with OR 1.31 and p value 0.01 whereas individuals with
genotype 1/1 had a reduced effect with OR 0.51 and p
value 6.46x10-7 (Figure 3B-2). Similar effect was obtained
in all lung cancer cohort (Figure 3B-1). For FHIT:TSPAN8
gene pair identified from SQC cohort, individuals with
genotype 0/1 had a significant reduced lung cancer risk
with OR 0.63 and p value 9.15x10-6 (Figure 3B-4).

Genetic interactions on gene expression in the
lung
We further explored the impact of identified genetic
interactions on the expression of involved cancer-related
genes using the lung eQTL dataset including a total of
409 subjects with both genotyping and gene expression
data [23-24]. We evaluated the interaction effects of
the significant SNP pairs on gene expression levels.
For the significant SNP pair rs10515157:rs1554783

Figure 3: Interaction analysis at candidate gene pairs. A. Stratified lung cancer risk analysis at the identified significant SNP pairs

using genotype data in discovery OncoArray data. MAF1 and MAF2 indicate the minor allele frequency of each SNP in the pair. 0 and 1
indicate the genotype without or with at least one copy of minor allele in second SNP. P values and ORs of SNP1 in main effect association
conditioned on genotype at SNP2 were displayed. B. the bar plots of risk effect at joint genotypes. In each plot, the genotype with no MAF
at either locus (0/0) was used as reference group. C. Analysis of the genetic interaction effect on gene expression in human lung tissues.
The interaction effects of SNP pairs on gene expression levels were evaluated using linear models. The evaluated genes and selected probes
were labeled at Y-axes. The boxplots of gene expression level were plotted for each joint genotype group to display the genetic interaction
effect on gene expression. Genotypes were coded in a dominant mode, i.e. 0 or 1 for absence or presence of the minor allele, respectively.
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Table 3: Top 5 canonical pathways involving the genes from identified genetic interactions in each lung cancer subtype
Subset

Canonical pathways

P

Overlap

ALL

Glioblastoma Multiforme Signaling (TSC1, EGF, PLCB1, FGFR2, GSK3B, EGFR)

3.35x10-7

6/162

HER-2 signaling (TSC1, EGF, FGFR2, GSK3B, EGFR)

4.18x10-7

5/88

Gαq Signaling (CALCR, NFATC2, PLCB1, FGFR2, GSK3B)

8.24x10-6

5/161

Regulation of the Epithelial-Mesenchymal Transition Pathway (NOTCH4, EGF, FGFR2, GSK3B, EGFR)

1.79x10-5

5/189

ErbB Signaling (EGF, FGFR2, GSK3B, EGFR)
Regulation of the Epithelial-Mesenchymal Transition Pathway (BCL9, EGFR, FGFR2)
UVB-Induced MAPK Signaling (EGFR, FGFR2)
EGF Signaling (EGFR, FGFR2)

2.46x10-5
6.02x10-3
7.43x10-3
7.87x10-3

4/98
3/189
2/66
2/68

Caveolar-mediated Endocytosis Signaling (EGFR, ITGA11)

8.55x10-3

2/71

ErbB4 Signaling (FGFR2, YAP1)

8.79x10-3

2/71

Role of CHK Proteins in Cell Cycle Checkpoint Control (BRCA1, E2F2, HUS1)

1.12x10-4

3/57

DNA damage-induced 14-3-3σ Signaling (BRCA1, HUS1)

4.40x10-4

2/19

Glioma Signaling (E2F2, EGFR, IGF2R)

8.60x10-4

3/114

Role of Oct4 in Mammalian Embryonic Stem Cell Pluripotency (BRCA1, POU5F1)

2.59x10-3

2/46

Spliceosomal Cycle (U2AF1/U2AF1L5)
Osteoarthritis Pathway (CASP8, FN1, GLI3, PaRX7, PPARD, SDC4, TCF7L2)

3.28x10-3
8.84x10-6

1/2
7/212

Protein Kinase A Signaling (AKAP12, CDC25C, DUSP10, GLI3, PDE4D, PLCB1, PTPRE, TCF7L2, TGFB2)

1.00x10-5

9/401

Aryl Hydrocarbon Receptor Signaling (ATR, ESR1, ESR2, TGFB2)

1.46x10-3

4/141

Inflammasome Pathway (CASP8, P2RX7)

2.16x10-3

2/20

Molecular Mechanisms of Cancer (ATR, CASP8, CDC25C, GAB2, PLCB1, TGFB2)

2.45x10-3

6/394

NSCLC

ADE

SQC

Fisher exact test p value is displayed to evaluate if the input genes are biologically connected rather than randomly associated.
Overlap indicates the number of input genes overlapped with the number of genes in a well-known canonical pathway.
from RNF43:SYNE1 gene pair, SYNE1 gene expression
levels are significantly different across four groups with
different joint genotypes (Figure 3C-2, P = 6.82x10-3).
With a dominant genotype model in both of the SNPs, the
individuals with 1/0 and 0/1 joint genotype have lower
SYNE1 expression compared with 0/0 and 1/1 groups.
Another differentially expressed gene is TSPAN8 from
SNP pair rs1882898:rs1705235 (Figure 3C-3, P = 4.67x102
). We detected decreased gene expression in 1/0, 0/1 and
1/1 groups compared with 0/0 genotype group. For the
SNP pair rs17835244:rs74826777 from RGL1:RAD51B
gene pair, the rs74826777 is not available in the lung
eQTL dataset and was replaced by the best available proxy
(rs12733281, D’ = 1, R2 = 0.33 in European population).
Because the low allele frequency in rs74826777 (and
proxy rs12733281) (MAF ~ 0.01), we had a limited
number of samples to test the interaction. We did not
identify differential gene expression in the gene pairs, but
we did see a trend of increased expression in 1/1 genotype
group (Figure 3C-1, P = 0.12). No significant interaction
signals were found for expression levels of RGL1, RNF43,
and FHIT (Appendix 3 Supplementary Figure 1).

between selected genes. However, we wanted to further
explore the underlying biological mechanisms behind the
statistical findings and understand the genetic architecture
of epistasis acting more generally. In ALL lung cancer
cohort, 37 SNP pairs had meta-analysis p value < 0.05 in
replication analysis and displayed consistent interaction
effect across three independent datasets. These 37 SNP
pairs came from 38 unique cancer-related genes and these
genes were submitted to IPA program for pathway and
network analysis. Similarly, 43, 36 and 76 genes were
submitted to IPA program from NSCLC, ADE and SQC
cohorts, respectively. The top 5 canonical pathways from
each lung cancer histology subtype are listed in Table
3 and all of them had a Fisher exact test p value less
than 0.01 suggesting the input genes were biologically
connected rather than randomly associated. The pathway
“hot spot” genes from ALL and NSCLC are EGF, FGFR2,
EGFR, and GSK3B, etc. The regulation of the epithelialmesenchymal transition (EMT) pathway is among the top
5 canonical pathways in both ALL (p = 1.79x10-5) and
NSCLC (p = 6.02x10-3) lung cancer cohorts. EMT is an
evolutionary conserved process which is induced in the
metastasis process, converting stationary epithelial cells to
invasive and mobile mesenchymal cells [25-28]. The top 2
canonical pathways in ADE cohort, both include BRCA1
and HUS1 gene, are Role of CHK Proteins in Cell Cycle
Checkpoint Control (p = 1.12x10-4) and DNA damage-

Gene set enrichment analysis
The statistical analysis using GWAS data provided
very significant statistical evidence for genetic interactions
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analysis either from our discovery dataset (P > 0.01) or
from other published lung cancer GWAS reports. These
findings reinforce that genetic epistasis among cancerrelated genes is a common mechanism involved in lung
tumorigenesis and many latent genes contribute to lung
cancer development through interacting with other
modifier genes.
We further extended the lung cancer risk analysis
to lung eQTL gene expression analysis. SYNE1 was
implicated in many cancers and gene expression
profiles analysis in TCGA displayed that SYNE1 was
downregulated in 18 cancer types, including NSCLC,
breast cancer and colon cancer, etc, compared with normal
tissues [32]. In the gene expression analysis between
SYNE1 and rs10515157:rs1554783 SNP pair, the SYNE1
gene expression were slightly decreased in groups with
1/0 and 0/1 joint genotype and increased in 1/1 group
compared with 0/0 reference group (Figure 3C-2). These
results were consistent with the observed increased lung
cancer risk in 1/0 and 0/1 group, and decreased risk in
1/1 group in our epistasis analysis (Figure 3B-3). In the
study between TSPAN8 gene and rs1882898:rs1705235
SNP pair, we also identified consistent evidence between
risk and gene expression analysis. TSPAN8 gene played
an important role in cancer initiation and overexpression
was discovered in colorectal, pancreatic and NSCLC, etc
[33-35]. The decreased expression in joint genotype 1/0
and 0/1 group were consistent with the decreased lung
cancer risk in these two groups. RAD51B, as a tumor
suppressor gene, belongs to RAD51 protein family that is
essential for DNA repair by homologous recombination.
Overexpression of RAD51B is found to be associated
with better prognosis in NSCLC [36-37]. For the
RAD51B gene, we did not identify interaction signals in
gene expression analysis because of the limited sample
size to test low frequency alleles and there were only 6
individuals with the highest risk joint genotype (Figure
3C-1). However, we see a trend of increased expression
in 1/1 group and decreased expression in 0/1 group, which
supports the decreased risk effect in 1/1 and increased risk
in 0/1 group, respectively (Figure 3B 1-2). In summary,
the gene expression analysis provides information about
the functional role of the identified genetic interactions in
lung cancer development, supporting the findings of this
study and yield insights about the molecular mechanisms
of lung carcinogenesis.
In the gene network analysis, the IPA program
constructed gene networks by searching the extensive
records maintained in its library to find the genes that
may directly or indirectly connected with the input
“seeds” from interaction analysis. Interestingly, all the
three significant epistasis—-RGL1:RAD51B in ALL
and NSCLC lung cancer, SYNE1:RNF43 in ADE and
FHIT:TSPAN8 in SQC risk development—-were displayed
as interaction between networks (Figure 4 and Appendix
3 Supplementary Figure 2). These results suggest that

induced 14-3-3σ Signaling pathway (p = 4.40x10-4). Both
these two pathways have been reported to be involved in
lung carcinogenesis and prognosis [29-31].
In addition to the already known canonical pathways,
we are also interested in the de novo gene networks that
may exist among the interactive genes. Figure 4A-4C
plots displayed the top putative gene networks curated by
epistasis-involved candidate genes from NSCLC, ADE
and SQC subgroup interaction analysis. In each plot,
red lines indicate genetic interactions either achieving
the significance level (p < 1.95x10-10) in the joint metaanalysis; blue lines indicate SNP pairs with consistent
evidence for genetic interaction across discovery and
replication data sets but not achieving significance level
in joint analysis. In NSCLC lung cancer cohort, IPA
created two top gene networks with RAD51B in one
network and RGL1 in the other (Figure 4A). Similar gene
networks results were found in ALL lung cancer cohort
(Appendix 3 Supplementary Figure 2). The significant
genetic interactions between SYNE1 and RNF43 in
the ADE cohort, and between TSPAN8 and FHIT in
SQC cohort were both demonstrated as interactions
between two putative networks (Figure 4B-4C). In
addition to the significant between-network interactions
in RAD51B:RGL1, SYNE1:RNF43 and TSPAN8:FHIT
pairs, we also see within-network interactions, such as
the interaction between THADA and PVT1 in the NSCLC
cohort, and between BRCA1 and SYNPO2 in ADE cohort,
etc (Figure 4A-4B).

DISCUSSION
Epistasis is an important mechanism contributing
to development of complex human diseases. However,
new discoveries of genetic interactions derived from
association analysis have been limited because of the
challenge in high-dimensional statistical analysis. In
this paper, we reported a filtered G x G interaction
analysis among oncogenesis-related genes in lung cancer
development aiming to identify important oncogene
or tumor suppressor genes involved in lung cancer
development by interacting with other modifier genes.
This study design also has the advantage to reduce the
search space and thus improve the statistical power in
epistasis analysis. We collected the GWAS data from
lung cancer OncoArray Consortium in discovery stage
and two independent GWAS data sets for replication
study. A total of 44,438 individuals including 24,037 lung
cancer patients and 20,401 health controls from European
descent population were recruited in this study, which is
by far the largest genetic interaction study in lung cancer
to our knowledge. We successfully identified epistasis
in RGL1:RAD51B in ALL and NSCLC lung cancer,
SYNE1:RNF43 in ADE and FHIT:TSPAN8 in SQC risk
development. None of the SNPs, from the significant SNP
pairs, were revealed previously in main effect association
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Figure 4: Gene network analysis using IPA program. A.-C. displayed the top networks from NSCLC, ADE and SQC cohort,

respectively. Genes labeled with pink color indicate the input candidate genes from interaction analysis. Arrow lines indicate the potential
genetic interactions identified in G x G analysis. Red lines indicate those genetic interactions either achieving the significance level in
the joint analysis or having multiple SNP pairs with consistent evidence for genetic interaction across discovery and replication data sets
although not achieving significance level in joint analysis; blue line indicate sporadic signals for potential genetic interactions without
achieving significance.
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lung cancer has a very complex molecular mechanism
and interactions among gene networks, rather than just
interactions between individual genes, are involved in lung
cancer development.
Lung cancer is a heterogeneous disease and different
genetic variants have been identified associated with
overall lung cancer risk as well as lung cancer subtypes
[4,38]. The large sample size in our study and the high
density of imputed SNP markers allow us to identify lung
cancer subtype-specific epistasis including RGL1:RAD51B
in NSCLC (OR = 0.40, p = 9.71x10-11), SYNE1:RNF43
in ADE cohort (OR = 0.73, p = 1.01x10-12), and
FHIT:TSPAN8 in SQC cohort (OR = 0.60, p = 7.62x1011
). The pathway and gene network analysis also display
the differences in epistasis and signaling pathways in lung
cancer subtype which enhances our understanding of the
molecular mechanisms underlying lung cancer subtypes.
Stringent Bonferroni correction, assuming the
independence among all the tests, was applied to control
the multiple comparison issue in our study. However, the
Bonferroni multiple test correction is overly conservative
for pair-wise interaction analysis. The pair-wise
interaction tests are positively correlated with each other.
Our application of the overly conservative Bonferroni
corrected p value < 1.95x10-10 may have led to our not
detecting some significant findings. We believe more
genetic interactions including those with small effects and
histology subtype-specific effects could be identified in
the future as more samples with genotype data become
available. With current knowledge, the information
about the functional significance of the identified SNPs
is remains limited in our study, but we were fortunate to
be able to analyze effects on joint genotypes from a study
of lung tissues. With the development of the functional
annotations on the GWAS SNP panel we wish to identify
genetic interactions with important diagnosis and
prognosis value in lung cancer disease in the future.

in the replication study: TRICL Affymetrix GWAS
data including 5,397 controls and 4,950 lung cancer
cases
(http://www.ncbi.nlm.nih.gov/projects/gap/cgibin/study.cgi?study_id=phs000876.v1.p1), and GELCC
(Genetic Epidemiology of Lung Cancer Consortium)
familial lung cancer GWAS including 744 controls and
686 lung cancer patients genotyped using Illumina
HumanOmniExpressExome-8v1 array [38-39]. The
demographic and clinical characteristics of each dataset
including age, gender, and smoking status, histology
subtypes, etc., were provided in Table 1. IBD analysis was
conducted between the datasets and duplicated samples
were removed before the epistasis analysis.

Ethics statement
All subjects provided informed consent, and the
institutional review boards of each participating institutes
approved this collaborative study. Further details about
the specific studies are provided in prior studies of the
Oncoarray, TRICL Affymetrix array, and GELCC study
[4,38-39]. Data from all of these studies have been
uploaded to dbGAP (phs001273.v1.p1, phs0 phs000878.
v1.p1).

Cancer related genes filtering process
We sought to obtain a list including the oncogenesisrelated gene as complete as possible for this filtered
epistasis analysis. The Bushman Lab generated a
comprehensive list of 2,027 cancer-related genes which
were selected based on information from the Atlas of
Genetics and Cytogenetics in Oncology and Hematology,
Catalog of Somatic Mutations in Cancer (COSMIC), and
the Consensus Coding Sequences of Human Breast and
Colorectal Cancer, etc [40]. The majority of these genes
are encoded for DNA binding proteins, transcription
factors, transcriptional regulators, and other genes
regulating protein expression (Figure 1A) [41]. The wellknown lung cancer related genes, such as lung tumor
mutation-harboring genes EGFR, KRAS, BRAF and riskassociated genes - nicotinic acetylcholine receptor family
(CHRNB4, CHRNA3, CHRNA5, etc.), CYP gene family
(CYP1A1, CYP2A6, CYP2D6, etc.), and TERT, etc., are
also included in these 2,027 genes. The ~500,000 postquality control SNPs from the discovery OncoArray
GWAS data were narrowed down to 43,652 SNPs located
within transcript region (including untranslated regions)
of these 2,027 cancer-related genes. We further removed
SNPs with minor allele frequency (MAF) < 0.005 because
these variants had little power in genetic interaction
analysis and the number of SNPs in final analysis was
35,031.

MATERIALS AND METHODS
Study populations
We collected the genotype data from three
independent lung cancer GWAS including a total
of 24,037 lung cancer patients and 20,401 health
controls with Caucasian ancestry in the study. TRICL
(Transdisciplinary Research In Cancer of the Lung)
OncoArray consortium GWAS data were analyzed in the
discovery stage, including 14,260 controls and 18,401
lung cancer patients (dbGaP Study Accession: phs001273.
v1.p1) (Table 1)4. All the samples were genotyped using
the Illumina OncoArray-500K BeadChip and 502,933
SNPs remained for analysis after quality control processes.
Two independent lung cancer GWAS data were analyzed
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Statistical analysis

three datasets in discovery and replication stage. Figure
1B displayed the flowchart of research strategy in the
epistasis study. We applied the same research strategy in
overall lung cancer cohort as well as stratified analysis by
lung cancer subtypes NSCLC (non-small cell lung cancer),
ADE and SQC.

Significance p value threshold calculation
Specifying a reasonable Bonferroni corrected p
value threshold is an important step in analysis of high
dimensional data. Among the 35,031 tested SNPs, some
of them are not independent from each other because
of linkage disequilibrium (LD). We applied the GEC
(Genetic Type I error calculator) program to evaluate the
eigenvectors of the correlation matrix and computed the
number of independent SNPs in the analysis [42]. We
found there were 22,622 independent SNPs among the
35,031 tested SNPs and the number of pairwise interaction
tests was 255,866,131. The Bonferroni corrected p value
cutoff assuming independence among all the tests was
computed as 0.05/255,866,131 = 1.95x10-10. Any SNP
pairs with joint interaction p value < 1.95x10-10 will be
reported as significant findings.

Genotype imputation
The genotypes from the three GWAS datasets came
from different platforms and the overlaps among the
SNP panels were limited. We used IMPUTE2 program
to impute the genotype in replication datasets to increase
the SNP overlaps between the discovery and replication
datasets. For those candidate SNP pairs with meta-analysis
p value < 0.1 in each replication study we further imputed
the flanking SNPs in ~30 kb of those candidate SNPs in
the discovery data to increase the density of SNP markers.
The 1000 Genomes Project Phase 3 release was used as
the reference dataset [44]. The output dosage file from
IMPUTE2 was used as input in logistic regression analysis
and the first three PCs were adjusted in the imputed
genotype analysis.

Epistasis analysis
In this proposed genetic interaction analysis, we
followed a two-stage study design: we conducted the
interaction analysis at discovery stage using OncoArray
GWAS data, and then replicated the signals using
independent Affymetrix and GELCC GWAS datasets. A
two-step analysis strategy was adopted in the discovery
stage: in step 1, an imprecise but fast pairwise epistasis
analysis was conducted using the “fast-epistasis” option
in PLINK program [43]. This test was based on a Z-score
test to compare the difference of SNP1-SNP2 allelic
association between cases and controls. SNP pairs with
p value < 1x10-6 were submitted to a more stringent
logistic regression analysis using formula (1) at step 2.
An R program was used for logistic regression interaction
analysis and the first three principal components (PCs)
were adjusted in the analysis. In order to harvest as many
potential signals as possible in discovery study we relaxed
the significance cutoff to 1x10-5 in regression analysis. The
SNP pairs with logistic regression interaction p value less
than 1x10-5 were further submitted to replication studies.
logit (D) = β0 + β1 × snp1 + β2 × snp2 + β3 × snp1 × snp2
+ ∑ βi x covi (1)
In the replication study, the same regression model
specified by formula (1) was applied in the analysis.
Considering the small sample size in the GELCC GWAS
dataset (n = 1430) compared with the TRICL Affymetrix
GWAS (n = 10,347), we performed a meta-analysis in the
replication study to combine the information from both
datasets. The SNP pairs with interaction meta-analysis p
value < 0.05 and consistent interaction effects (OR > or
< 1 across different discovery and replication datasets)
were reported as replicated signals. We then performed a
final meta-analysis to combine the information from all
www.oncotarget.com

Genetic interactions on gene expression in the
lung
Identified epistasis on lung cancer risk were
extended to gene expression levels using the lung eQTL
dataset [23-24]. Briefly, lung specimens were collected
from patients undergoing lung cancer surgery and stored
at the biobank of the “Institut universitaire de cardiologie
et de pneumologie de Québec” (IUCPQ). Genotyping was
carried out using the Illumina Human1M-Duo BeadChip.
Expression profiling was performed using an Affymetrix
custom array (see GEO platform GPL10379). A total
of 409 subjects passed genotyping and gene expression
quality controls. Expression values were adjusted for age,
sex and smoking status. Probe sets and SNPs implicated
in the identified genetic interactions for lung cancer risk
were selected including RGL1:RAD51B, RNF43:SYNE1,
and FHIT:TSPAN8. The interaction effects of SNP pairs on
gene expression levels were evaluated using linear models.
Genotypes were coded in a dominant mode, i.e. 0 or 1 for
absence or presence of the minor allele, respectively.

Gene set enrichment analysis
Gene set enrichment analysis provided information
about the biological implications underlying statistical
findings in our genetic interaction analysis. We conducted
canonical pathway and gene network analysis using
Ingenuity Pathway Analysis (IPA, QIAGEN Inc., https://
www.qiagenbioinformatics.com/products/ingenuity1772
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pathway-analysis) software to explore the possible
relationships among the candidate genes. The oncogenesisrelated genes from the SNP pairs with interaction metaanalysis p value < 0.05 in replication study were provided
as the focus genes in IPA. IPA searched the extensive
records maintained in its Ingenuity Pathways Knowledge
Base (IPKB) and created the canonical pathway based on
well-known biological and molecular pathways. In gene
network analysis, the IPA program utilized the provided
list of focus gene as “seeds” and searched IPKB to find the
genes that may directly or indirectly connected with the
“seeds” and then created a gene network. The IPA program
will also conduct a Fisher exact test to compute the
probability that the association between a given gene set
and a given pathway, based on well-established signaling
and metabolic pathways in IPA library, is due to random
chance and provide a p value for the test.
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